Publication: Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: A randomized trial
dc.contributor.author | Moses R. Kamya | en_US |
dc.contributor.author | Adoke Yeka | en_US |
dc.contributor.author | Hasifa Bukirwa | en_US |
dc.contributor.author | Myers Lugemwa | en_US |
dc.contributor.author | John B. Rwakimari | en_US |
dc.contributor.author | Sarah G. Staedke | en_US |
dc.contributor.author | Ambrose O. Talisuna | en_US |
dc.contributor.author | Bryan Greenhouse | en_US |
dc.contributor.author | François Nosten | en_US |
dc.contributor.author | Philip J. Rosenthal | en_US |
dc.contributor.author | Fred Wabwire-Mangen | en_US |
dc.contributor.author | Grant Dorsey | en_US |
dc.contributor.other | Makerere University | en_US |
dc.contributor.other | Uganda Malaria Surveillance Project | en_US |
dc.contributor.other | Uganda Ministry of Health | en_US |
dc.contributor.other | London School of Hygiene & Tropical Medicine | en_US |
dc.contributor.other | University of California, San Francisco | en_US |
dc.contributor.other | Mahidol University | en_US |
dc.contributor.other | Mekerere University | en_US |
dc.date.accessioned | 2018-08-24T02:05:46Z | |
dc.date.available | 2018-08-24T02:05:46Z | |
dc.date.issued | 2007-05-18 | en_US |
dc.description.abstract | Objectives: To compare the efficacy and safety of artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) for treating uncomplicated falciparum malaria in Uganda. Design: Randomized single-blinded clinical trial. Setting: Apac, Uganda, an area of very high malaria transmission intensity. Participants: Children aged 6 mo to 10 y with uncomplicated falciparum malaria. Intervention: Treatment of malaria with AL or DP, each following standard 3-d dosing regimens. Outcome measures: Risks of recurrent parasitemia at 28 and 42 d, unadjusted and adjusted by genotyping to distinguish recrudescences and new infections. Results: Of 421 enrolled participants, 417 (99%) completed follow-up. The unadjusted risk of recurrent falciparum parasitemia was significantly lower for participants treated with DP than for those treated with AL after 28 d (11 % versus 29%, risk difference [RD] 18%, 95% confidence interval [CI] 11%-26%) and 42 d (43% versus 53%; RD 9.6%, 95% CI 0%-19%) of follow-up. Similarly, the risk of recurrent parasitemia due to possible recrudescence (adjusted by genotyping) was significantly lower for participants treated with DP than for those treated with AL after 28 d (1.9% versus 8.9%; RD 7.0%, 95% CI 2.5%-12%) and 42 d (6.9% versus 16%; RD 9.5%,95% CI 2.8%-16%). Patients treated with DP had a lower risk of recurrent parasitemia due to non-falciparum species, development of gametocytemia, and higher mean increase in hemoglobin compared to patients treated with AL. Both drugs were well tolerated; serious adverse events were uncommon and unrelated to study drugs. Conclusion: DP was superior to AL for reducing the risk of recurrent parasitemia and gametocytemia, and provided improved hemoglobin recovery. DP thus appears to be a good alternative to AL as first-line treatment of uncomplicated malaria in Uganda. To maximize the benefit of artemisinin-based combination therapy in Africa, treatment should be integrated with aggressive strategies to reduce malaria transmission intensity. | en_US |
dc.identifier.citation | PLoS Clinical Trials. Vol.2, No.5 (2007) | en_US |
dc.identifier.doi | 10.1371/journal.pctr.0020020 | en_US |
dc.identifier.issn | 15555887 | en_US |
dc.identifier.other | 2-s2.0-34249862105 | en_US |
dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/20.500.14594/24869 | |
dc.rights | Mahidol University | en_US |
dc.rights.holder | SCOPUS | en_US |
dc.source.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=34249862105&origin=inward | en_US |
dc.subject | Medicine | en_US |
dc.title | Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: A randomized trial | en_US |
dc.type | Article | en_US |
dspace.entity.type | Publication | |
mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=34249862105&origin=inward | en_US |